Incorporation of fludarabine and 1-β-D-arabinofuranosylcytosine 5'- triphosphates by DNA polymerase α: Affinity, interaction, and consequences

Clinical Cancer Research

Volumn 3, Issue 8, 1997, Pages 1347-1355

  Gandhi, Varsha ^a   Huang, Peng ^a   Chapman, Amy J ^a   Chen, Feng ^a   Plunkett, William ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; CYTARABINE TRIPHOSPHATE; DNA POLYMERASE; FLUDARABINE; PRIMER DNA;

ARTICLE; CYTOTOXICITY; DNA INTEGRATION; DNA SYNTHESIS INHIBITION; DRUG MECHANISM; KINETICS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ARABINONUCLEOTIDES; BASE COMPOSITION; BASE SEQUENCE; DNA POLYMERASE I; DNA PRIMERS; HUMANS; KINETICS; SUBSTRATE SPECIFICITY; TEMPLATES, GENETIC; VIDARABINE PHOSPHATE;

EID: 0030877223     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Kornberg, A., and Baker, T. DNA Replication, Ed. 2. New York: W. H. Freeman and Co., 1992.
2. Wang, T. S-F. Eukaryotic DNA polymerases. Annu. Rev. Biochem., 60: 513-552, 1991.
3. Copeland, W. C., and Wang, T. S-F. Catalytic subunit of human DNA polymerase α overproduced from baculovirus-infected insect cells: structural and enzymological characterization. J. Biol. Chem., 266: 22739-22748, 1991.
4. Perrino, F. W., and Loeb, L. A. Differential extension of 3′ mispairs is a major contribution to the high fidelity of calf thymus DNA polymerases. J. Biol. Chem., 264: 2898-2905, 1989.
5. Boosalis, M. S., Petruska, J., and Goodman, M. F. DNA polymerase insertion fidelity: gel assay for site-specific kinetics. J. Biol. Chem., 262: 14689-14696, 1987.
6. Ferst, A. R. Fidelity of replication of phage X174 DNA by DNA polymerase IU holoenzyme: spontaneous mutation by microincorporation. Proc. Natl. Acad. Sci. USA, 76: 4946-4950, 1979.
7. Kunkel, T. A., Silber, J. R., and Loeb, L. A. The mutagenic effect of deoxynucleotide substrate imbalance during DNA synthesis with mammalian DNA polymerases. Mutat. Res., 94: 413-419, 1982.
8. Hillebrand, G. G., and Beattie, K. L. Influence of template primary and secondary structure on the rate and fidelity of DNA synthesis. J. Biol. Chem., 260: 3116-3125, 1985.
9. Major, P. O., Egan, E. M., Herrick, D. J., and Kufe, D. W. Effect of ara-C incorporation on deoxyribonucleic acid synthesis in cells. Biochem. Pharmacol., 31: 2937-2940, 1982.
10. Huang, P., Chubb. S., and Plunkett, W. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine: a mechanism for cytotoxicity. J. Biol. Chem., 265: 16617-16625, 1990.
11. Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., and Plunkett, W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res., 51: 6110-6117, 1991.
12. Xie, K. C., and Plunkett, W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine. Cancer Res., 56: 3030-3037, 1996.
13. Keating, M. J., McCredie, K. B., Bodey, G. P., Smith, T. L., Gehan, E. A., and Freireich, E. J. Improved prospects for long-term survival in adults with acute myelogenous leukemia. J. Am Med Assoc., 248: 2481-2486, 1982.
14. Stone, R. M., and Mayer, R. J. Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hematol-Oncol. Clin. N. Am., 7: 47-64, 1993.
15. Keating, M. J., Kantarjian, H., Talpaz, M., Redman, J., Koller, C., Barlogie, B., Velasquez, E., Plunkett, W., Freireich, E. J., and McCredie, K. B. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood, 74: 19-25, 1989.
16. Keating, M. J., Kantarjian, H., O'Brien, S., Koller, C., Talpaz, M., Schachner, J., Childs, C. C., Freireich, E. J., and McCredie, K. B. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol., 9: 44-49, 1991.
17. Estey, E., Plunkett, W., Gandhi, V., Rios, M. B., Kantarjian, H., and Keating, M. J. Fludarabine and 1-β-D-arabinofuranosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leukemia Lymphoma, 9: 343-350, 1993.
18. Estey, E., Thall, P., Andreeff, M., Beran, M., Kantarjian, H., O'Brien, S., Escudier, S., Robertson, L. E., Koller, C., Kornblau, S., Pierce, S., Freireich, E. J., Diesseroth, A., and Keating, M. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J. Clin. Oncol., 12: 671-678, 1994.
19. Gandhi, V., Kemena, A., Keating, M. J., and Plunkett, W. Fludarabine infusion potentiates 1-β-D-arabinofuranosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res., 52: 897-903, 1992.
20. Gandhi, V., Estey, E., Keating, M. J., and Plunkett, W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J. Clin. Oncol., 11: 116-142, 1993.
21. Chu, M. Y., and Fischer, G. A. Comparative studies of leukemia cells sensitive and resistant to 1-β-D-arabinofuranosylcytosine. Biochem. Pharmacol., 14: 333-341, 1965.
22. Schrecker, A. W., and Urshel, M. J. Metabolism of 1-β-D-arabinofuranosylcytosine in leukemia L1210: studies with intact cells Cancer Res., 28: 333-341, 1968.
23. Plunkett, W., Chubb, S., Alexander, L., and Montgomery, J. A. Comparison of the toxicity and metabolism of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res., 40: 2349-2355, 1980.
24. Graham, F. L., and Whitmore, G. F. The effect of 1-β-D-arabinofuranosylcytosine on growth, viability, and DNA synthesis of mouse L-cells. Cancer Res., 30: 2627-2635, 1970.
25. Wills, P., Hickey, R., Ross, D., Cuddy, D., and Malkas, L. A novel in vitro model for studying the action of ara-C. Cancer Chemother Pharmacol., 38: 366-372, 1996.
26. Kufe, D. W., Major, P. P., Egan, E. M., and Beardsley, G. P. Correlation of cytotoxicity with incorporation of ara-C into DNA. J. Biol. Chem., 255: 8997-9000, 1980.
27. Major, P. P., Egan, E. M., Beardsley, G. P., Minden, M. D., and Kufe, D. W. Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc. Natl. Acad. Sci. USA, 78: 3235-3239, 1981.
28. Kufe, D., Spriggs, D., Egan, E. M., and Munroe, D. Relationships among ara-CTP pools, formation of (ara-C)DNA, and cytotoxicity of human leukemic cells. Blood, 64: 54-58, 1984.
29. Spriggs, D., Robbins, G., Mitchell, T., and Kufe, D. W. Incorporation of 9-β-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNA. Biochem. Pharmacol., 35: 247-252, 1986.
30. Kantarjian, H. M., Estey, E. H., Plunkett, W., Keating, M. J., Walters, R. S., Iacoboni, S., McCredie, K. B., and Freireich, E. J. Phase I-II clinical and pharmacologic studies of high-dose 1-β-D-arabinofuranosylcytosine in refractory leukemia. Am. J. Med., 81: 387-394, 1986.
31. Estey, E. H., Keating, M. J., McCredie, K. B., Freireich, E. J., and Plunkett, W. Cellular ara-CTP pharmacokinetics, response, and karyo-type in newly diagnosed acute myelogenous leukemia. Leukemia (Baltimore), 4: 95-99, 1990.
32. Plunkett, W., and Gandhi, V. Cellular pharmacodynamics of anti-cancer drugs. Semin. Oncol., 20: 50-63, 1993.
33. Gandhi, V., and Plunkett, W. Modulation of arabinosyl nucleoside metabolism by arabinosylnucleotides in human leukemia cells Cancer Res., 48: 329-334, 1988.
34. Novotny, L., and Plunkett, W. 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate: the synthesis of a triphosphate derivative from a monophosphate derivative. In: L. B. Townsend and R. S. Tipson (eds.), Nucleic Acid Chemistry, pp. 337-340. New York: John Wiley & Sons, 1991.
35. Huang, P., Farquhar, D., and Plunkett, W. Selective action of 3′-azido-3′-deoxythymidine 5′-triphosphate on viral reverse transcriptases and human DNA polymerases. J. Biol. Chem., 205: 11914-11918, 1990.
36. Goodman, M. F., Creighton, S., Bloom, L. B., and Petruska, J. Biochemical basis of DNA replication fidelity. Crit. Rev. Biochem. Mol. Biol., 28: 83-126, 1993.
37. Chou, J., and Chou, T. Dose-Effect Analysis with Microcomputers, pp. 5-18. Amsterdam: Elsevier Science Publishers B. V., 1985.
38. Gandhi, V., Estey, E., Keating, M. J., Chucrallah, A., and Plunkett, W. Chlorodeoxyadenosine and 1-β-D-arabinofuranosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood, 87: 156-164, 1996.
39. Furlong, N. B., and Gresham, C. Inhibition of DNA synthesis but not of poly-dAT synthesis by the arabinose analogue of cytidine. Nat. New Biol., 233: 212-213, 1971.
40. Townsend, A. J., and Cheng, Y-C. Sequence-specific effects of ara-5-aza-CTP and ara-CTP on DNA synthesis by purified human DNA polymerases in vitro: visualization of chain elongation on a defined template. Mol. Pharmacol., 32: 330-339, 1988.
41. Mikita, T., and Beardsley, G. P. Functional consequences of the 1-β-D-arabinofuranosylcytosine structural lesion in DNA. Biochemistry, 27: 4698-4705, 1988.
42. Ohno, Y., Spriggs, D., Matsukage, A., Ohno, T., and Kufe, D. Sequence-specific inhibition of DNA strand elongation by incorporation of 9-β-D-arabinofuranosyladenine. Cancer Res., 49: 2077-2081, 1989.
43. Perrino, F. W., and Mekosh, H. L. Incorporation of 1-β-D-arabinofuranosylcytosine monophosphate into DNA at internucleotide linkages by human DNA polymerase α. J. Biol. Chem., 267: 23043-23051, 1992.
44. Sundaralingam, M. Structure and conformation of nucleosides and nucleotides and their analogs as determined by X-ray diffraction. Ann. NY Acad. Sci., 225: 3-42, 1976.
45. Dalton, J. G., George, A. L., Hruska, F. E., McGaig, T. N., Ogilvie, K. K., Peeling, J., and Wood, D. J. Comparison of arabinose and ribose nucleoside conformation in aqueous and dimethylsulfoxide solution: 2′,5′-hydrogen bonding in arabinonucleosides. Biochim. Biophys. Acta, 478: 261-273, 1977.
46. Gao, Y-G., van der Marel, G. A., van Boom, J. H., and Want, A. H-J. Molecular structure of a DNA decamer containing an anticancer nucleoside 1-β-D-arabinofuranosylcytosine: conformational perturbation by 1-β-D-arabinofuranosylcytosine in B-DNA. Biochemistry, 30: 9922-9931, 1991.
47. Zhang, H., van der Marel, G. A., van Boom, J. H., and Wang, A. H-J. Conformational perturbation of the anticancer nucleoside 1-β-D-arabinofuranosylcytosine on Z-DNA: molecular structure of (ara-CdG)3 at 1.3 Å resolution. Biopolymers, 32: 1559-1569, 1992.
48. Parker, W. B., Shaddix, S. C., Chang, C-H., White, E. L., Rose, L. M., Brockman, R. W., Shortnacy, A. T., Montgomery, J. A., Secrist, J. A., III, and Bennett, L. L., Jr. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res., 51: 2386-2394, 1991.
49. Gandhi, V., and Plunkett, W. Cell cycle-specific metabolism of arabinosylnucleosides in K562 human leukemia cells. Cancer Chemother. Pharmacol., 31: 11-17, 1992.
50. Tosi, P., Visani, G., Ottaviani E., Manfroi, S., Zinzani, P. L., and Tura, S. Fludarabine + ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myelogenous leukemia cells. Leukemia (Baltimore), 8: 2076-2082, 1994.
51. Visani, G., Tosi, P., Zinzani, P. L., Manfroi, S., Ottaviani, E., Testoni, N., Clavio, M., Cenacchi, A., Gamberi, B., Carrara, P., Gobbi, M., and Tura, S. FLAG (fludarabine, high-dose cytarabine, G-CSF): an effective and tolerable protocol for the treatment of poor risk acute myeloid leukemia. Leukemia (Baltimore), 8: 1842-1846, 1994.
52. Parker, W. B., Ashok, R. B., Shen, J-X., Townsend, A. J., and Cheng, Y-c. Interaction of 2-halogenated dATP analogs (F, Cl and BR) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol. Pharmacol., 34: 485-491, 1988.
53. Tseng, W-C., Derse, D., Cheng Y-C., Brockman, R. W., and Bennett, L. L., Jr. In vitro biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol. Pharmacol., 21: 474-477, 1982.
54. Xu, Y-Z., Huang, P., and Plunkett, W. Functional compartmentalization of dCTP pools. Preferential utilization of salvaged deoxycytidine for DNA repair in human lymphoblasts. J. Biol. Chem., 270: 631-637, 1995.
55. Yang, S-W., Huang, P., Plunkett, W., Becker, F. F., and Chan, J. Y. H. Dual mode of inhibition of purified DNA ligase I from human cells by 9-β-D-arabinofuranosyl-2-fluoroadenine triphosphate. J. Biol. Chem., 267: 2345-2349, 1992.
56. Kamiya, K., Huang, P., and Plunkett, W. Inhibition of the 3′→5′ exonuclease of human DNA polymerase ∈ by fludarabine-terminated DNA. J. Biol. Chem., 271: 19428-19435, 1996.
57. Yang, L-Y., Li, L., Keating, M. J., and Plunkett, W. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol. Pharmacol., 47: 1072-1079, 1995.
58. Sandoval, A., Consoli, U., and Plunkett, W. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin. Cancer Res., 2: 1731-1741, 1996.